ArticleAnnals of clinical and translational neurology2026
Digital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Use.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrimary mitochondrial disease is a group of genetic disorders caused by pathogenic variants in nuclear or mitochondrial DNA, often resulting in progressive neurodegeneration and cognitive decline. Current management is primarily supportive, though recent research offers hope for disease-modifying treatments in the future. Selecting appropriate therapeutic outcomes for clinical trials in mitochondrial diseases is challenging due to limited sensitivity to changes, small sample sizes, and the burden of study related activities. This study aims to identify an efficient choice of cognitive endpoints for translational research.
methodsThis study compared digital cognitive assessments with traditional paper-based tools. It included two cohorts: the Newcastle cohort of 45 patients recruited from the mitochondrial clinic Newcastle upon Tyne (UK) and the KHENERGYZE clinical trial cohort of 27 patients recruited from four European countries. Patients in the Newcastle cohort underwent two conventional cognitive assessments (Addenbrooke's Cognitive Examination and Montreal Cognitive Assessment), along with two computerized tests (Cogstate and Test of Attentional Performance). Potential confounding factors were also assessed.
resultsBoth cohorts showed a high prevalence of moderate to severe perceived fatigue. Over 50% of patients showed reduced reaction times. Strong correlations were found between conventional and digital assessments. Several confounding factors such as education and employment were identified as influencing cognitive performance.
conclusionsThe findings support the understanding of mitochondrial disease as a slowly progressive condition, where impaired cognitive function is evident even in patients in the absence of devastating CNS manifestations such as stroke-like episodes. Observed variability in cognitive performance may help detect meaningful changes over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.